You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《全日總結》恆指升152點 渣打反覆漲逾2% 醫藥股彈
人民幣匯價及內地股市造好,帶動港股反覆回升。恆指低開69點,初段曾跌124點低見15,041點,其後曾倒升418點見15,584點,全日升152點或1%,收15,317點;國指升37點或0.72%,收5,217點;恆生科技指數升71點或2.48%,收2,956點。大市全日成交總額1,307.51億元,滬、深港通南下交易分別淨流入38.07億及27.12億元人民幣。 金融股方面,渣打(02888.HK)季度稅前溢利超市場預期,股價升2.7%報50.2元。匯控(00005.HK)下調明年淨利息收入預測後股價昨(25日)日挫逾5%,今日反彈0.8%報40.25元。港交所(00388.HK)升4.3%報233.6元,友邦(01299.HK)升1.7%報59.1元。 科技股普遍上升,阿里健康(00241.HK)預告扭虧半年最少賺8,000萬人民幣,股價升8.8%。阿里巴巴(09988.HK)跌2%報62.3元,騰訊(00700.HK)升2.5%報211.6元,美團(03690.HK)升5%報129.7元,小米(01810.HK)升3.5%報9.14元。手機相關股瑞聲(02018.HK)、丘鈦(01478.HK)及比亞迪電子(00285.HK)各升4.6%至6.4%。 美國電動車生產商特斯拉(TSLA.US)股價彈逾5%,汽車股小鵬(09868.HK)及蔚來(09866.HK)急彈9.9%及10.5%。長汽(02333.HK)及理想(02015.HK)各升5.1%及4%。 上海啟動吸入式新冠疫苗接種,醫藥股顯著上升,康希諾(06185.HK)急彈20.6%。中國中藥(00570.HK)及威高(01066.HK)各升逾7%,白雲山(00874.HK)、石藥(01093.HK)、百濟神州(06160.HK)、潤藥(03320.HK)及翰森(03692.HK)各升逾5%。 萬洲(00288.HK)績後遭券商下調目標價,股價跌5.3%。潤啤(00291.HK)斥123億人幣收購貴州金沙窖酒酒業55.19%股權,潤啤股價跌6%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account